Efficacy, safety, and tolerability of brexpiprazole augmentation for aripiprazole one-monthly in Japanese schizophrenia: A Randomized Controlled Clinical Trial
Not Applicable
- Conditions
- schizophrenia
- Registration Number
- JPRN-UMIN000043575
- Lead Sponsor
- Department of Neuropsychiatry, Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Serious complication Active suicidal ideations or past suicide attempts Drug or alcohol abuse Pregnant or breast-feeding females mental retardation Using of oral aripiprazole or asenapine, blonanserin Having been judged as unsuitable for the study forin other reasons by an principal investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive and Negative Syndrome Scale (PANSS) from week 0 to week 12
- Secondary Outcome Measures
Name Time Method Remission rate, Clinical Global Impression-Severity scale (CGI-S), Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS), UKU Side Effect Scale(UKU), Barnes Akathisia Rating Scale (BARS), Epworth Sleepness Scale(ESS), body weight, Body Mass Index, blood biochemistry, Japanese Adult Reading Test (JART), electroencephalography